Immunophotonics Inc was founded in 2008 as a US-based research-oriented company. Our main objective is to develop and introduce inCVAX, a promising new treatment method for metastatic tumors.

The products in our pipeline are based on more than 15 years of academic research, and more than a hundred papers have been published in peer-reviewed journals. Immunophotonics was founded as the next step in our vision to introduce this innovative and promising treatment modality to cancer patients around the world.